Recombinant protein · Agonist of insulin receptor (INSR) · developed by Mannkind
Regular human insulin is a recombinant human insulin that lowers blood glucose by stimulating glucose uptake in skeletal muscle and fat and by inhibiting hepatic glucose production. It also inhibits lipolysis and proteolysis and enhances protein synthesis. It is used to improve glycemic control in diabetes mellitus.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of May 30, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01490762 | Phase 1 | Healthy | Completed | MNKD |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Healthy
Updated Oct 18, 2026. Something wrong or missing? Report it on the MNKD page.
See MNKD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MNKD catalysts and pipeline →